ReviewInternational journal of molecular sciences2017
Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 3 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.BMC cancer · 2023Pooled it
- Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.International journal of molecular sciences · 2021Pooled it
- Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review.Cell communication and signaling : CCS · 2019Pooled it
- Biology Over Imaging: Duodenal Adenocarcinoma Recurrence Presenting as a Pancreatic Head Mass in Lynch Syndrome.Cureus · 2026Article
- First-line nanoparticle polymeric micellar paclitaxel with gemcitabine in metastatic pancreatic cancer: a single-arm, prospective, and exploratory study.Gastroenterology report · 2026Article
- 20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transporters.Journal of advanced research · 2025Article
- Immunohistochemical Evaluation of the Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Patient Education on Exercise Prehabilitation Among Patients Receiving Neoadjuvant Therapy for Cancer Surgery in China: A Mixed-Methods Study.Healthcare (Basel, Switzerland) · 2025Article
- C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients.Asia-Pacific journal of clinical oncology · 2025Article
- Improving molecular subtypes and prognosis of pancreatic cancer through multi group analysis and machine learning.Discover oncology · 2025Article
- Erianin Suppresses Pancreatic Cancer Progression by Inducing Cell Cycle Arrest and Ferroptosis.Cancer management and research · 2025Article
- Values of apparent diffusion coefficient in pancreatic cancer patients receiving neoadjuvant therapy.BMC cancer · 2024Article
- Comprehensive analysis and experimental verification of the mechanism of anoikis related genes in pancreatic cancer.Heliyon · 2024Article
- Transcription factor FOXF2 promotes the development and progression of pancreatic cancer by targeting MSI2.Oncology reports · 2024Article
- Pancreatic Ductal Adenocarcinoma (PDAC): A Review of Recent Advancements Enabled by Artificial Intelligence.Cancers · 2024Review
- MicroRNA-485-5p targets keratin17 to regulate pancreatic cancer cell proliferation and invasion via the FAK / SRC / ERK pathway.Journal of Cancer · 2024Article
- Current landscape of gastrointestinal radiation oncology in Spain: a multicenter real-life survey and comparison with key clinical guidelines.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Article
- Unveiling the role of interleukin-6 in pancreatic cancer occurrence and progression.Frontiers in endocrinology · 2024Review
- Identification of a potential prognostic model combining pyroptosis-related gene with immune microenvironment for pancreatic ductal adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- Pancreatic Ductal Adenocarcinoma: Update of CT-Based Radiomics Applications in the Pre-Surgical Prediction of the Risk of Post-Operative Fistula, Resectability Status and Prognosis.Journal of clinical medicine · 2023Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The standard treatment of resectable pancreatic cancer is surgery followed by adjuvant chemotherapy. Due to the complication rate of pancreatic surgery and the high rate of primary irresectability, neoadjuvant concepts are increasingly used for pancreatic cancer. Neoadjuvant therapy is better tolerated than adjuvant and might decrease the surgical complication rate from pancreatic surgery. In contrast to neoadjuvant chemoradiation, the nutritional status improves during neoadjuvant chemotherapy. Also, the survival of patients who develop postoperative complications after neoadjuvant therapy is comparable to those without complications whereas the survival of patients who underwent upfront surgery and then develop surgical complications is impaired. Moreover, large data base analyses suggest a down-sizing effect and improvement of overall survival by neoadjuvant therapy. Neoadjuvant chemotherapy appears to be equally efficient in converting irresectable in resectable disease and more efficient with regard to systemic tumor progression and overall survival compared to neoadjuvant chemoradiation therapy. Despite these convincing findings from mostly small phase II trials, neoadjuvant therapy has not yet proven superiority over upfront surgery in randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.